Atomoxetine in Patients With Tourette's Syndrome

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Poitiers University Hospital
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine

• The use of effective contraception or abstinence for subjects of reproductive age

• Written informed consent

Exclusion Criteria:

• Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria.

• Actual severe depression

• Allergy to one of the constituents

• Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma

• IMAO treatment discontinued less than 2 months or contra-indicated associated treatment